Acute paronychia and reactive capillary proliferation in a patient on erlotinib

Sir, Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor which targets epidermal growth and metastasis in solid cancers such as lung, pancreas, breast, and gastrointestinal tract. On examination, left great toe revealed an ill-defined tender, erythematous swelling in the periungual reg...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of dermatology Vol. 65; no. 3; pp. 236 - 237
Main Authors Kaur, Ishmeet, Gandhi, Vijay, Jakhar, Deepak
Format Journal Article
LanguageEnglish
Published Kolkata Wolters Kluwer India Pvt. Ltd 01.05.2020
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Correspondence
Debridement
Granulomas
Growth factors
Monoclonal antibodies
Staphylococcus infections
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Summary:Sir, Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor which targets epidermal growth and metastasis in solid cancers such as lung, pancreas, breast, and gastrointestinal tract. On examination, left great toe revealed an ill-defined tender, erythematous swelling in the periungual region with a well-defined vascular growth at the junction of proximal and lateral nail folds with bloody discharge, suggestive of pyogenic granuloma. {Figure 1}{Figure 2} EGFR inhibitors including small molecule tyrosine kinase inhibitors (erlotinib and gefitinib) and their chimeric monoclonal antibody (cetuximab) are increasingly been used in the management of various solid malignancies, such as non-small cell lung cancer and pancreatic cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0019-5154
1998-3611
DOI:10.4103/ijd.IJD_348_18